原文路透社:
https://reut.rs/3rsaHhk
药商也是想把整个疫苗研发流程给缩短啦
特别是小药商
各位乡民怎么看这篇？
大意:
1.目前开发出来的疫苗，经过大量公测后,
各药商针对公测的数据后有个初步的结论
2.又由于原本疫苗临床试验的安慰剂组跟疫苗组，
开始认为这种临床试验是不道德的。
而且接种的人愈来愈多，抗体的样本也愈来愈多，无法再做安慰剂组
再加上这次是合作的小药商开发出来的疫苗，他们也没有这么多资金再研发下去
(Such randomized, controlled trials may no longer be considered ethical in
some countries,
as researchers cannot give a dummy shot to people where an
effective vaccine is widely available.
In addition, many of the new shots are being developed by small companies that may not be able to conduct very large
trials without government funding or a partner with deep pockets.
3.英国与欧萌正在制定免疫桥接的规则跟标准，美国则观望中
European and UK health regulators are working with companies to set standards
for these so-called “immunobridging” studies.
The U.S. Food and Drug
Administration declined to say whether it would accept such trials for
next-generation vaccines.